Arrowhead Research (ARWR) Selloff Unwarranted - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
RBC Capital Downgrades Arrowhead Research (ARWR) to Sector Perform
October 8, 2014 5:41 PM EDTRBC Capital downgraded Arrowhead Research (NASDAQ: ARWR) from Outperform to Sector Perform with a price target of $9.00 (from $35.00). The change follows the release of its AASLD abstract earlier.
Analyst Michael J. Yee said, "Although the stock is down significantly to ~$350M mkt cap now because of low-end efficacy in AASLD abstract, we find it reasonable to now... More
Arrowhead Research (ARWR) Price Target Cut to $20 at Deutsche Bank; Program Isn't Dead, Says Analyst
October 8, 2014 1:16 PM EDTDeutsche Bank maintained a Buy rating on Arrowhead Research (NASDAQ: ARWR) but lowered its price target to $20.00 (from $45.00). Earlier Arrowhead Research reported disappointing ARC-520 data in a AASLD abstract. Analyst Alethia Young sees higher risks but doesn't think the program is dead.
"The viral reductions w/ ARC-520... More
